Stock TBIO TELESIS BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Telesis Bio, Inc.

Equities

TBIO

US1920032000

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-05-21 pm EDT 		5-day change 1st Jan Change
4.27 USD -5.32% Intraday chart for Telesis Bio, Inc. +1.30% -40.55%
May. 09 Earnings Flash (TBIO) TELESIS BIO Reports Q1 Revenue $3.4M MT
May. 09 Telesis Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Evolution of the average Target Price on Telesis Bio, Inc.

Price target over the last 5 years

History of analyst recommendation changes

3adb093acd729989c1d472f059b.uscyGodEa4d6r4luGtWRBadE7ha4pPCbvf57KhoOZVc._aFIb8s3KcYR27ome4HzbZEPgnf618Tc_rEfXXJeXB6XsnYv0zwozx_N4g~2bafef2f828a75d2d80bda5636e88fb8

Analyst Recommendations on Telesis Bio, Inc.

KeyBanc Downgrades Telesis Bio to Sector Weight From Overweight, Cites 'Limited Top-Line Visibility' Amid 'Tepid Biopharma Spending Environment' MT
KeyBanc Capital Markets Adjusts Price Target on Codex DNA to $5 From $8, Maintains Overweight Rating MT
KeyBanc Adjusts Codex DNA's Price Target to $8 From $30, Keeps Overweight Rating MT
CODEX DNA : Cowen Starts Codex DNA at Outperform MT
CODEX DNA : Jefferies Starts Codex DNA at Buy With $23 Price Target MT
CODEX DNA : KeyBanc Starts Codex DNA at Overweight With $30 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
4.27
Average target price
-

Consensus detail

Consensus revision (last 18 months)

Analysts covering Telesis Bio, Inc.

KeyBanc Capital Markets
Cowen
Jefferies & Co.

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. TBIO Stock
  4. Consensus Telesis Bio, Inc.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW